Guosa Life Sciences

Advancing Life Through Better Medicine

SPONSOR OVERVIEW · 2026

Advancing Clinical Development Worldwide

An integrated clinical research and global health enterprise — creating knowledge, developing people, connecting the global research community, and delivering clinical programs across established and emerging markets.

Collaborate. Innovate. Improve Lives. · guosalifesciences.com

WHO WE ARE

The responsiveness of a specialist. The discipline of a global CRO.

Founded in 2012 and headquartered in Melville, New York, Guosa Life Sciences combines global quality standards with local operational excellence across the United States, Sub-Saharan Africa, and Asia — built to deliver trials in established and emerging markets alike.

35+
Countries of operation

60+
Active research sites

180+
Investigators

15+
Strategic partners

FOUNDED
2012 · Melville, NY

DELIVERED
57 studies

ACTIVE
9 programs

EXPERTISE
12+ therapeutic areas

THE GLS ENTERPRISE

One Enterprise. Four Integrated Platforms.

Institute creates knowledge. Academy develops people. The Network connects the ecosystem. Solutions deliver the work. Because these work together rather than independently, sponsors get fewer handoffs, clearer accountability, and a faster path from protocol to data.

THINK

GLS Institute

Clinical Development and Global Health — research, publications, benchmarks, and policy that inform decisions.

LEARN

GLS Academy

Professional Education and Certification — training, certification, and workforce development.

CONNECT

Clinical Development Network

The global collaboration platform, organized through Centers of Excellence.

DELIVER

Solutions

Integrated clinical, regulatory, laboratory, safety, quality, and logistics delivery.

More than a CRO — a knowledge-driven enterprise that advances science, builds capacity, fosters collaboration, and delivers measurable impact.

INTEGRATED CAPABILITIES · DELIVER

One partner across the clinical development lifecycle.

A full-service capability set — engaged as strategic consulting, regional execution support, or fully integrated, end-to-end delivery.

Clinical Development
Trial management, start-up, monitoring, RBQM, DCT and hybrid.

Scientific and Medical
Protocol strategy, medical monitoring, feasibility, medical writing.

Regulatory Affairs
Strategy, IND and CTA, health-authority submissions, permits.

Quality and Compliance
GCP QA, inspection readiness, audits, CAPA, TMF, ALCOA+.

Biometrics and Data Science
Data management, biostatistics, programming, analytics.

Pharmacovigilance
SAE processing, signal detection, aggregate reporting.

Laboratory Solutions
Biospecimen management, biomarker and diagnostic support.

Logistics and Supply Chain
Cold-chain, IP distribution, depots, import and export.

Technology-Enabled Delivery
CSV, software QA, eClinical compliance, digital oversight.

Training and Capacity
GCP and GVP training, investigator and site readiness.

Emerging Markets
Regional regulatory, activation, community engagement.

Consulting and Advisory
Trial rescue, mock audits, gap and readiness assessments.

TEAM AND IN-COUNTRY REACH

A lean senior team with people on the ground.

GLS runs on a senior core team that scales with study complexity, backed by monitors embedded in-country rather than flown in — the difference between coordinating a region and actually operating in it.

27
Core team

12
CRAs across 12 Sub-Saharan countries

8
African office hubs

- Project management, regulatory affairs, and clinical operations leads
- Clinical research associates embedded in-country, fluent in local language and regulation
- Global medical advisors, quality assurance, and pharmacovigilance

AFRICAN OFFICE HUBS

Rwanda · Kenya · Uganda · Nigeria · Ghana · Senegal · Mali · South Africa

Headquarters: Melville, New York, USA

EXECUTIVE LEADERSHIP

Senior experts leading global clinical development.

Sponsors engage directly with the people accountable for scientific, regulatory, and operational delivery.

CO

Charles Oviawe

Managing Director

A Quality Assurance leader with 20+ years building and running global Quality Management Systems to FDA, EMA, MHRA, NMPA and PMDA standards — spanning GCP, GLP, GPV, GMP and CSV, with inspection readiness, audits, CAPA and change control.

VA

Dr. Vincent Ahonkhai

Global Regulatory and Medical Advisor

Former Senior Advisor for Global Health at the Gates Foundation and VP of Regulatory Affairs at GSK, with senior roles at Merck and Johnson and Johnson. A trained pediatrician with deep U.S. and Sub-Saharan African regulatory expertise across Phase I–IV.

TA

Dr. Teye Adusu

Director, Alliance Management

Builds and manages the strategic partnerships and investigator alliances behind the GLS network — including coordination of the AE-PCRN pan-African research network.

Backed by a network of Key Opinion Leaders providing additional scientific and regulatory expertise on demand.

ACTIVE PROGRAMS

A portfolio for the world's leading health sponsors.

GLS delivers active programs across oncology, vaccines, maternal and child health, dermatology, pharmacovigilance, and manufacturing support — for UN agencies, global health foundations, and biopharma.

ONCOLOGY
BeyondSpring Pharmaceuticals

MALARIA VACCINE
European Vaccine Initiative

MATERNAL AND CHILD HEALTH
UNICEF · WHO · OXON Epidemiology

VACCINE LOGISTICS
UNICEF

DERMATOLOGY
Clinuvel

PHARMACOVIGILANCE
Safety oversight across programs

MANUFACTURING SUPPORT
Three manufacturers · Rwanda

TRUSTED BY
UN agencies, global health foundations, and biopharma sponsors.

PROOF OF DELIVERY · 01

Maternal and Child Health — WHO

A multi-country maternal and child health program delivered end to end for the World Health Organization.

8
Countries · 11 sites

23,000
Women and children enrolled

5
Year delivery

GLS role

Feasibility, monitoring, quality assurance, community engagement, and cross-site harmonization across Kenya, Uganda, Tanzania, Mali, Ghana, Ethiopia, India and Bangladesh.

Key achievement

Protocol harmonization and stronger governance drove a measurable reduction in protocol deviations across all sites.

PROOF OF DELIVERY · 02

Dermatology — Vitiligo

A five-country vitiligo trial delivered full-service, from activation through close-out.

5
Countries · 6 sites

540
Participants enrolled

2
Year delivery

Full-service scope

Feasibility, project management, regulatory and ethics submissions, site and vendor management, monitoring, QA, training, recruitment, and community engagement across Kenya, Uganda, Tanzania, Zambia and Ethiopia.

Key achievement

Fast enrollment with timelines met — strong governance and reduced deviations.

CONNECT · CLINICAL DEVELOPMENT NETWORK

A global network, with a differentiated African asset.

The Clinical Development Network is the global collaboration platform connecting sponsors, investigators, institutions, laboratories, and partners into one coordinated ecosystem. Guosa Life Sciences serves as the Network Coordinating Center, and the CDN is organized through Centers of Excellence.

FLAGSHIP CENTER OF EXCELLENCE

AE-PCRN · African Early Phase Clinical Research

A pan-African early-phase network purpose-built for Phase I, vaccines, emerging infectious disease, and epidemic preparedness — connecting leading institutions and investigators into one sponsor-ready platform.

10	22	56	✓
Countries	Institutions	Principal investigators	Feasibility completed

One front door. A single coordinated point of engagement across qualified sites. Participating institutions retain full authority; GLS coordinates and sources.

THE OPPORTUNITY

The most under-served market in clinical research.

Africa carries roughly a quarter of the world's disease burden and hosts barely one percent of its clinical trials — despite having the highest human genetic diversity on Earth.

~19%
of the world's population

25%
of the global disease burden

1.1%
of clinical trials (2023)

> Funders including NIH, BARDA, CEPI, WHO and the Gates Foundation increasingly expect trials to reflect the populations they aim to protect. Representative science is becoming a requirement, not a preference.

Sources: WHO (845 of 76,331 trials initiated globally in 2023); World Economic Forum; The Lancet Regional Health – Africa.

REGULATORY PATHWAY

We know the path to approval.

GLS navigates the full regulatory and ethics landscape in each market — from national authorities and ethics committees to AVAREF joint reviews and import and export permits, with realistic, country-aware timelines.

01
Strategy and dossier
Country-specific CTA and IND planning.

→

02
National authority
NRA submission, review, and approval.

→

03
Ethics review
National and institutional IRB and IEC.

→

04
AVAREF joint review
Coordinated multi-country vaccine reviews.

→

05
Permits and activation
Import and export, activation, first patient in.

GLS leverages AVAREF and African Medicines Agency harmonization to compress multi-country timelines, and manages ethics, permits, and local representation in every market. Timelines are country-specific and modeled during feasibility.

QUALITY AND COMPLIANCE

One quality system, inspection-ready by design.

GLS runs a controlled, metrics-driven Quality Management System aligned to global regulators — led by a QA professional with 20+ years across FDA, EMA, MHRA, NMPA and PMDA.

US FDA · EMA · MHRA · NMPA · PMDA · GCP · GLP · GPV · GMP · CSV

Controlled documents and SOPs
Versioned, access-controlled documentation.

Deviations and CAPA
Root-cause analysis and corrective action.

Change control
Governed changes across business units.

Audits and inspection readiness
Internal, vendor, and regulatory audits.

Training and qualification
Role-based GCP and GVP training and records.

Quality metrics
KPIs, trend analysis, and risk mitigation.

RISK AND MITIGATION

Emerging-market risk — named and managed.

These are the risks sponsors ask about most, and how GLS mitigates each.

Regulatory and ethics variability	→	Country-specific strategy, AVAREF pathways, and regulatory staff in each region.
Supply and cold-chain continuity	→	Validated cold-chain, redundant logistics, import and export permits, and in-country depots.
Site capacity and data quality	→	Pre-qualified network sites, in-country CRAs, RBQM, and central oversight.
Political and operational instability	→	Multi-country footprint, local presence, and active contingency planning.
Data integrity and privacy	→	21 CFR Part 11, ALCOA+, GDPR, and local data-protection compliance.
Community trust and recruitment	→	Community engagement, local-language consent, and ethics-first design.

MEASURABLE VALUE

Faster start-up, leaner cost, one point of contact.

Target outcomes GLS is built to deliver — modeled per study during feasibility and stated as objectives.

30–40% faster

Target reduction in multi-country feasibility timelines using pre-qualified network sites.

20–30% faster

Target acceleration of site activation and start-up versus building country by country.

One contract

A single master agreement and one point of contact across every market.

Lower in-region cost

Delivery at a compelling regional cost base, without compromising global quality.

Ready-to-activate sites

Network sites already qualified with feasibility completed — activation, not assessment.

Representative data

Diverse, funder-mandated populations that strengthen every submission.

PARTNER WITH US

Ready to advance your clinical development program?

Whether you are planning a single-country study, a multi-regional trial, or a global health initiative, GLS delivers the scientific expertise, operational flexibility, and quality oversight to accelerate development and improve health outcomes.

Submit an RFP · guosalifesciences.com/contact/rfp

info@guosalifesciences.com

200 Broadhollow Road, Suite 207, Melville, NY 11747 USA

Collaborate. Innovate. Improve Lives.